Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Rating) has received a consensus rating of “Hold” from the eight research firms currently covering the company, reports Marketbeat.com. Two investment analysts have rated the stock with a sell rating, two with a hold rating and one with a buy rating. The average one-year target price among brokers who have covered the stock over the past year is $8,750.00.
A number of research firms have commented on RBGLY. UBS Group raised its price target on Reckitt Benckiser Group from GBX8,400 (US$101.50) to GBX8,700 (US$105.12) in a report on Thursday, July 28. Berenberg Bank raised its price target on Reckitt Benckiser Group to GBX 8,050 ($97.27) from GBX 7,375 ($89.11) in a report on Friday, July 29. Sanford C. Bernstein upgraded Reckitt Benckiser Group from an underperform rating to a market perform rating in a research note on Thursday, July 28. Finally, in a research note on Thursday, July 28, Barclays raised its price target on the Reckitt Benckiser Group to GBX 9,500 ($114.79) from GBX 8,600 ($103.91).
Reckitt Benckiser Group stock performance
RBGLY stock opened at $13.23 on Friday. The Reckitt Benckiser Group has a 52-week low of $13.09 and a 52-week high of $17.90. The company’s 50-day moving average is $15.49 and its two-hundred-day moving average is $15.53. The company has a debt to equity ratio of 0.95, a current ratio of 0.62 and a quick ratio of 0.44.
Reckitt Benckiser Group lowers dividend
The company also recently announced a dividend, which was paid on Wednesday, September 21st. Registered investors received a dividend of $0.1596 per share on Monday, August 8th. This corresponds to a dividend yield of 2.45%. The ex-dividend date of this dividend was Friday August 5th.
Corporate Profile of the Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and distributes health, hygiene and nutritional products in the UK, United States, China, India and internationally. The company offers acne treatment creams, face washes and cleansing pads; disinfection, hygiene and first aid products; condoms, sex toys and lubricants; solutions for heartburn and indigestion; and cough and congestion relief, multi-symptom and sinus relief for adults and children under the Clearasil, Dettol, Durex, Gaviscon and Mucinex brands.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected]
Hear this before you consider Reckitt Benckiser Group.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and Reckitt Benckiser Group wasn’t on the list.
While Reckitt Benckiser Group is currently rated a Hold by analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here